Compare Genuine Parts Company (GPC) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Repligen Corporation Common Stock — how do they compare? Genuine Parts Company trades at $131.49 (market cap $18.15B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B). The key difference: Genuine Parts Company is the larger of the two by market cap, and Genuine Parts Company pays a 3.23% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Genuine Parts Company for 75 Days and Repligen Corporation Common Stock for 0 Days on average.
| GPC | RGEN | |
|---|---|---|
Market Cap | $18.15B | $11.31B |
Volume | 829,167 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $194.57 |
52-Week Low | $92.47 | $102.87 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $24.24B | $11.20B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $130.71, up 0.84% today, with a bullish technical signal and support near $127. The company reported mixed quarterly earnings, beating in Q1 and Q2 but missing in Q4 2025, while revenue grew to $24.3B in 2025. Net income margin remains thin at 0.13%, and the P/E ratio is elevated at 522.84, indicating high earnings expectations. Recent news highlights the planned spinoff of its industrial unit, Motion, by Q1 2027, which could unlock value.
The outlook is cautiously optimistic, driven by the corporate split catalyst and steady dividend yield, but risks include compressed profitability, high debt levels, and economic sensitivity. Analysts maintain a buy consensus with a $145.75 price target, suggesting 11.5% upside, though execution on the separation and margin improvement are critical for sustained gains.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
